Lechien JR, Paleri V, Baudouin R, Brunet A, Chiesa-Estomba CM, Crosetti E, De Vito A, Cammaroto G, De Virgilio A, Fakhry N, Golusinski W, Irjala H, Lang S, Leemans CR, Moriniere S, Saibene AM, Sampieri C, Siddiq S, Vander Poorten V, Viros Porcuna D, Vergez S, Briganti G, Maniaci A, Remacle M, Simon C, Hans S
European surgical guidelines: transoral robotic surgery for head and neck cancers.
ORAL ONCOLOGY
DOI: 10.1016/j.oraloncology.2025.107826
IF: 1.09
RESEARCH GROUPS
Head and Neck Cancer: Biomedical Research Cancer Stem cells
11
Number of publications
54.55
%
% Q1
27.27
%
% D1
63.64
%
% Leadership
42.86
%
% Female Leadership
3.89
CROWN (2021-2025)
20.00
%
HCP10% (2021-2025)
81.82
%
% Open access
45.45
%
% International Collaboration
1
Highly cited papers / HCP 1% (2021-2025)
1
Publications in high-IF journals with high Altmetric scores
7
Number of Ongoing Projectes (total)
0
International ongoing projects
5
Number of New projects (total)
1
International new projects
1
Number of Active clinical Trials
0
Number of New Clinical Trials
0
Number of Theses
The laboratory’s overall aim is to identify, through genetic, RNA or proteomic screening, new therapeutic targets in patients with head and neck cancer. Candidate genes and proteins are characterised at the molecular level using cell lines and patient biopsies to determine their mechanism of action. Once their biological relevance in proliferation has been identified, we design chemical compounds capable of blocking their signalling pathways to provide new therapeutic approaches.
Clinically, our reference population encompasses more than one million people from Vall d’Hebron Hospital and its tertiary care area — a population with a growing proportion of elderly patients. The Otorhinolaryngology Head-Neck Surgery Department diagnoses and operates over 200–250 head and neck cancer patients annually, a figure that continues to rise. The department has pioneered robotic surgery and pre-operative 3D planning for complex cases.
CORE/MISSIONS
- AI, Data, Imaging & Digital Health
- Innovative & Advanced Therapies
PROGRAMS
TEAM
Group Leader
Matilde E. LLeonart Pajarín and David Virós Porcuna
Principal Investigator (PI)
Matilde E. LLeonart Pajarín and David Virós Porcuna
Researchers
Yoelsis García Mayea, Juan Fernando Fuentes Cabrera, Pablo Vergés Fort, Laura Grau De Diego
PhD Students
Marina Bataller Fernández, Yang Hong, Gaomiyang Liu, Maria Escribano Cebrian, Aqsa Ahsan
SELECTED PUBLICATIONS
Virós Porcuna D, Suen KH, Stein H, Pollán Guisasola
New Approaches for Robot-Assisted Neck Surgery: Clavicular and Submental Approaches Using the da Vinci SP
J Craniofac Surg. 2025 Jan-Feb 01;36(1):16-20.
DOI: 10.1097/SCS.0000000000010297
IF: 3.37
Llansana A, Porcuna DV, Vasquez R, Parellada A, Valero C, Holgado A, Leon X
PATH classification: a proposal for patients with HNSCC treated with salvage surgery.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
DOI: 10.1007/s00405-024-08961-x
IF: 1.22
Marco Ferrari; Francesca Mularoni; Davide Smussi; et al;(22/22) Consensus Group for Laryngeal Preservation (es miembro de este grupo David Virós). 2025.
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer.
The Lancet Oncology. Science Direct (Elsevier). 2025.26-5, pp.e264-e281.
DOI: 10.1016/S1470-2045(25)00020-8.
IF: 8.62
Russo E, Porcuna DV, Gorphe P, Paleri V, Pellini R, Costantino A, Accorona R, De Virgilio A.
Transoral Robotic Surgery for Elderly Patients with Oropharyngeal and Laryngeal cancer
J Clin Med
DOI: 10.3390/jcm15041586.
IF: 0.9
SELECTED PROJECTS
Novel agents designed to combat head and neck cancer function as Trojan horses to overcome chemoresistant cells.
Principal Investigator: Matilde E. LLeonart
Agency: HNA Foundation
Funding: 50,000 €
Period: 2025-2027
Establecimiento de una estrategia combinada en carcinoma escamoso de cabeza y cuello: una herramienta eficar para superar los tumores quimioresistentes
Principal Investigator: Matilde E. LLeonart
Agency: Instituto de Salud Carlos III
Funding: 240,000 €
Period: 2025-2027
Nanocapsules combining novel drugs with conventional chemotherapy to cure resistant cancers
Principal Investigator: Matilde E. LLeonart (PI and Coordinator of 3 Countries involved)
Agency: European Project (Nanotecmec)
Funding: 318,750€
Period: 2025-2027
Risk of cisplatin-induced hearing loss. (CHAFT). Interreg SUDOE + FEDER.
Principal Investigator: David Virós Porcuna
Agency: Interreg SUDOE + FEDER
Funding: 149,321 €
Period: 2025-2028
PATENTS
COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS THAT OVEREXPRESS TSPAN1
Priority Number: PCT/EP2024/085543
Priority Date: 11/12/2023
Applicants: 70% VHIR, 30% IQAC-CSIC
DISSEMINATION ACTIVITIES
International day of Head and Neck Cancer
Place: Hospital Vall d´Hebron
Date: 25/07/2025
Brief: The whole research Team including several clinitial and basic reseachers explained people the importance of cancer prevention controling tobacco and alcohol consumption
International Day of Women and Girls in Science (11 February 2025).
Place: "Biomedical research in tumor stem cells: Head and Neck Cancer" laboratory (VHIR)
Date: 11/02/2025
Brief: Several researchers from our group explained to a group of Students who visit our lab, the importance of research in science
